- Home
- FGL vs BCAB Comparison
FGL vs BCAB Comparison
Compare FGL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGL
- BCAB
- Stock Information
- Founded
- FGL 2021
- BCAB 2007
- Country
- FGL Malaysia
- BCAB United States
- Employees
- FGL N/A
- BCAB N/A
- Industry
- FGL
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- FGL
- BCAB Health Care
- Exchange
- FGL NYSE
- BCAB Nasdaq
- Market Cap
- FGL 25.4M
- BCAB 22.3M
- IPO Year
- FGL 2024
- BCAB 2020
- Fundamental
- Price
- FGL $0.73
- BCAB $0.38
- Analyst Decision
- FGL
- BCAB Buy
- Analyst Count
- FGL 0
- BCAB 2
- Target Price
- FGL N/A
- BCAB $1.00
- AVG Volume (30 Days)
- FGL 1.2M
- BCAB 610.4K
- Earning Date
- FGL 07-07-2025
- BCAB 08-07-2025
- Dividend Yield
- FGL N/A
- BCAB N/A
- EPS Growth
- FGL N/A
- BCAB N/A
- EPS
- FGL N/A
- BCAB N/A
- Revenue
- FGL $20,205,441.00
- BCAB $11,000,000.00
- Revenue This Year
- FGL N/A
- BCAB N/A
- Revenue Next Year
- FGL N/A
- BCAB N/A
- P/E Ratio
- FGL N/A
- BCAB N/A
- Revenue Growth
- FGL N/A
- BCAB N/A
- 52 Week Low
- FGL $0.66
- BCAB $0.24
- 52 Week High
- FGL $5.26
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- FGL N/A
- BCAB 41.17
- Support Level
- FGL N/A
- BCAB $0.38
- Resistance Level
- FGL N/A
- BCAB $0.46
- Average True Range (ATR)
- FGL 0.00
- BCAB 0.05
- MACD
- FGL 0.00
- BCAB -0.01
- Stochastic Oscillator
- FGL 0.00
- BCAB 7.22
About FGL FOUNDER GROUP LTD
Founder Group Ltd is a solar solutions provider in Malaysia, offering end-to-end services for commercial and industrial sectors, as well as large-scale solar power projects, encompassing project design, engineering, and comprehensive project management. Its focus is on two key segments: large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects are utility scale solar PV power plants with installed generating capacity of 1 MWac or more. C&I projects are smaller scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their own consumption, such as factories, warehouses and commercial stores. Its revenue is derived from Malaysia.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.